Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

@article{Rekhtman2011SuitabilityOT,
  title={Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.},
  author={Natasha Rekhtman and Suzanne M Brandt and Carlie S Sigel and Maria A Friedlander and Gregory J Riely and William D Travis and Maureen F. Zakowski and Andr{\'e} L. C. Moreira},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2011},
  volume={6 3},
  pages={451-8}
}
INTRODUCTION The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR and KRAS molecular testing. The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice. METHODS Subtyping of primary lung carcinomas by preoperative… CONTINUE READING